Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULTIMATE: ctDNA-Informed Management in Early-Stage Rectal Cancer
NCT07209215Phase 2Not yet recruiting
- Sponsor
- University of California, Davis
- Start
- Oct 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in rectal cancer (2 arms), sponsored by University of California, Davis. Primary endpoints: Pathologic complete response rate up to 2 years and Disease-free survival rate up to 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07209215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209215.